All News

Glucose monitoring can help providers and pharmacists optimize medication management for personalized diabetes care.

Inhaling smoke can have acute effect for people with asthma, chronic obstructive pulmonary disease (COPD), or pulmonary fibrosis.

Tucatinib is an oral HER2-targeting tyrosine kinase inhibitor that was approved by the FDA in 2020.

Presence of comorbidities in older patients with breast cancer complicates treatment decisions.

Rates of invasive breast cancer or death were 50% lower with adjuvant trastuzumab emtansine compared with trastuzumab alone.

Pharmacists can play an important role in tobacco cessation.

Biosimilar use is not linked to an increased risk of treatment failure among pediatric patients with inflammatory bowel disease (IBD).

Endocrine-immune-based therapies yielded favorable objective response rates but had limited impact on pathological complete response.

The US health care market faces transformative changes in 2025, as biosimilars, GLP-1s, and new pharmacy economics reshape how benefit managers balance innovation with affordability.

Pharmacists bridge communication gaps and enhance shared decision-making.

Ruling potentially affects federal ability to regulate pharmacy.

Point-of-care testing implementation could provide valuable data on community respiratory syncytial virus incidence and enhance sentinel surveillance efforts.

Patients recovering from COVID-19 and caregivers reported how some social determinants of health were helpful in their recovery, while others led to difficult social and mental challenges.

The report highlights perspective from 4 key stakeholders of patients, specialty pharmacies and providers, biopharmaceutical industry, and public and private payers.

The FDA is modernizing its approach to drug development and optimization.

Abelacimab (Anthos Therapeutics Inc) is a novel factor XI inhibitor being investigated for the reduction of bleeding for patients with atrial fibrillation.

USP provides health literacy standards and solutions that enhance medication safety and improve patient outcomes.

The fast-track designation follows the FDA orphan drug designation that was granted for DYNE-101 in September 2023 for the same treatment population.

The Commission aims to provide information for clinical decision making, therapeutic interventions, and public health strategies.

The drug is being investigated as a PET diagnostic of cardiac amyloid light-chain and amyloid transthyretin-related (ATTR) amyloidosis.

Despite these findings, navacaprant was generally well-tolerated and safe in patients with major depressive disorder.

Memantine/donepezil and everolimus are used to treat dementia of the Alzheimer type and tuberous sclerosis complex-associated subependymal giant cell astrocytoma, respectively.

Patient-centered care involves educating and empowering individuals to take responsibility for their own care.

Biotin supplementation could mitigate manganese-induced damage caused by manganese deficiency and excessive exposure.

Approximately 33.2% of patients who received semaglutide 7.2 mg achieved 25% or more weight loss after 72 weeks.

This case report depicts a probable infusion reaction in a 61-year-old woman prescribed evinacumab for the treatment of familial hypercholesterolemia.

Patients with multiple sclerosis being treated with glatiramer acetate have an increased risk of experiencing anaphylaxis.